N-[4-(4-Pyridinyl)phenyl]ureas and their cardiotonic use

Abstract

Disclosed and claimed are N-R-N-40 [4-(4-2-R 2 -3-R 3 -5-R 5 -6-R 6 -4-pyridinyl)phenyl]ureas (I) or pharmaceutically-acceptable acid-addition salts thereof, where R is hydrogen, methyl or ethyl, R 2 is hydrogen, methyl, ethyl or hydroxyl, R 6 hydrogen, methyl or ethyl, and R 3 and R 5 are each hydrogen or methyl, their cardiotonic use and their preparation.

We claim: 
     
       1. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, a cardiotonically-effective amount of N-R-N'-[4-(2-R 2  -3-R 3  -5-R 5  -6-R 6  -4-pyridinyl)phenyl]urea having the formula ##STR2## where R is hydrogen, methyl or ethyl, R 2  is hydrogen, methyl, ethyl or hydroxyl, R 6  is hydrogen, methyl or ethyl, R 3  and R 5  are each hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       2. A composition according to claim 1 where R is hydrogen or methyl, R 2  is hydrogen, methyl, ethyl or hydroxyl, and R 3 , R 5  and R 6  are each hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       3. A composition according to claim 1 where the cardiotonic is N-[4-(4-pyridinyl)phenyl]urea or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       4. A composition according to claim 1 where the cardiotonic is N-methyl-N-'-[4-(4-pyridinyl)phenyl]urea or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       5. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient a cardiotonically-effective amount of N-R-N'-[4-2-R 2  -3-R 3  -5-R 5  -6-R 6  -4-pyridinyl)phenyl]urea having the formula ##STR3## where R is hydrogen, methyl or ethyl, R 2  is hydrogen, methyl, ethyl or hydroxyl, R 6  is hydrogen, methyl or ethyl, R 3  and R 5  are each hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       6. The method according to claim 5 where R is hydrogen or methyl, R 2  is hydrogen, methyl, ethyl or hydroxyl, and R 3 , R 5  and R 6  are each hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       7. The method according to claim 5 where the cardiotonic is N-[4-(4-pyridinyl)phenyl]urea or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       8. The method according to claim 5 where the cardiotonic is N-methyl-N'-[4-(4-pyridinyl)phenyl]urea or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       9. An N-R-N'-[4-(2-R 2  -3-5 R 5  -6-R 6  -4-pyridinyl)phenyl]urea having the formula ##STR4## where R is hydrogen, methyl or ethyl, R 2  is hydrogen, methyl, ethyl or hydroxyl, R 6  is hydrogen, methyl or ethyl, R 3  and R 5  are each hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       10. A compound according to claim 9 where R is hydrogen or methyl, R 2  is hydrogen, methyl, ethyl or hydroxyl, and R 3 , R 5  and R 6  are each hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       11. N-[4-(4-pyridinyl)phenyl]urea or pharmaceutically-acceptable acid-addition salt thereof. 
     
     
       12. N-methyl-N'-[4-(4-pyridinyl)phenyl]urea or pharmaceutically-acceptable acid-addition salt thereof.